Dong-A Pharmaceutical Co.,Ltd. (KRX:000640)

South Korea · Delayed Price · Currency is KRW

87,600

-900 (-1.02%)

Oct 28, 2026, 2:09 PM KST

Market Cap	589.54B -16.6%
Revenue (ttm)	1.52T +10.1%
Net Income	85.25B -3.5%
EPS	11,064.86 -16.9%
Shares Out	6.73M
PE Ratio	7.92
Forward PE	6.75
Dividend	1,650.49 (1.88%)
Ex-Dividend Date	Jul 30, 2026

Volume	7,574
Open	90,100
Previous Close	88,500
Day's Range	87,200 - 90,100
52-Week Range	74,500 - 121,845
Beta	0.11
Analysts	Strong Buy
Price Target	145,000.00 (+65.53%)
Earnings Date	Oct 27, 2026

About Dong-A Pharmaceutical

Dong-A Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the pharmaceutical business in South Korea. It operates through a Holding Company; Over-the-Counter Drugs and Quai-Drugs; Biosimilars and Consignment Medicines; Logistics; Packaging Solutions; and Others segments. The company develops DA-8010 in Phase 3 clinical trial to treat overactive bladder; DMB-3115, a biosimilar of Stelara in Phase 3 clinical trial; DA-1241 in Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis; DA-1726 in Phase 1 clinical tr... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1932

Employees 79

Stock Exchange Korea Stock Exchange

Ticker Symbol 000640

Full Company Profile

Financial Performance

In 2025, Dong-A Pharmaceutical's revenue was 1.43 trillion, an increase of 7.24% compared to the previous year's 1.33 trillion. Earnings were 90.94 billion, an increase of 56.74%.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for 000640 stock is "Strong Buy." The 12-month stock price target is ₩145,000, which is an increase of 65.53% from the latest price.

Price Target

₩145,000

(65.53% upside)

Analyst Consensus: Strong Buy

Stock Forecasts